Mutation analysis of the cathepsin C gene in Indian families with Papillon-Lefèvre syndrome [PDF]
, 2003 Background: PLS is a rare autosomal recessive disorder characterized by early onset periodontopathia and palmar plantar keratosis. PLS is caused by mutations in the cathepsin C (CTSC) gene.
Veeriah Selvaraju +7 more
core +1 more source
Weight Loss With GLP‐1 Agonists in Nondiabetic Adults: Systematic Review and Network Meta‐Analysis
Obesity, EarlyView.ABSTRACT Objective Two glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) (semaglutide and liraglutide) and one dual agonist (tirzepatide) are FDA‐approved for weight loss in adults with obesity without type 2 diabetes mellitus. This systematic review and network meta‐analysis aims to compare the efficacy of these agents against each other.
Michael Lim +3 more
wiley +1 more source
Vildagliptin induced cutaneous leukocytoclastic vasculitis: A case report
Medicine Science, 2018 Vildagliptin is a new generation theurapeutic agent of diabetes mellitus which belongs to dipeptidyl peptidase-IV inhibitor class acting via the incretin hormone system.
Serhat Sayin +2 more
doaj +1 more source
Dipeptidyl peptidase-4 activity might be a link between tumour necrosis factor alpha and insulin resistance in type 1 diabetes [PDF]
, 2016 Tumour necrosis factor alpha (TNF α) leads to β cell damage in type 1 diabetes (T1DM) but also causes insulin resistance (IR). It modulates dipeptidyl peptidase-4 (DPP-4) activity, adipokine linked with both IR and T1DM. We were interested if there is an
Blaslov, Kristina +3 more
core +1 more source
Obesity, EarlyView.Web portal for interrogating Adverse Events of GLP‐1 RA in diabetes vs weight control/obesity. ABSTRACT Objective This study aimed to assess the spectrum and frequency of adverse events (AEs) linked to glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) using the US FDA Adverse Event Reporting System (FAERS).
David Stone +3 more
wiley +1 more source
Acta Pharmaceutica Sinica B, 2014 Dipeptidyl peptidase 4 (DPP4) is recognised as an attractive anti-diabetic drug target, and several DPP4 inhibitors are already on the market. As members of the same gene family, dipeptidyl peptidase 8 (DPP8) and dipeptidyl peptidase 9 (DPP9) share high ...
Jinglong Liu +4 more
doaj +1 more source
Staging concept for aging management: Definition, mechanism, and coping strategies
VIEW, EarlyView.We divided the overall aging stage into “pre‐aging”, “aging compensation”, and “aging disability”. For each stage, we delineate the clinical presentations, biological phenomena, theoretical underpinnings, and key management priorities. Abstract Aging, as a gradual and largely irreversible biological process, characterized by declining organismal ...
Zhonghan Wang +6 more
wiley +1 more source
Diabetology & Metabolic SyndromeBackground Dipeptidyl peptidase 4 (DPP-4) plays a crucial role in breaking down various substrates. It also has effects on the insulin signaling pathway, contributing to insulin resistance, and involvement in inflammatory processes like obesity and type ...
L. M. Pechmann +3 more
doaj +1 more source
The dipeptidyl peptidase IV inhibitors vildagliptin and K-579 inhibit a phospholipase C: a case of promiscuous scaffolds in proteins. [PDF]
, 2013 The long term side effects of any newly introduced drug is a subject of intense research, and often raging controversies. One such example is the dipeptidyl peptidase-IV (DPP4) inhibitor used for treating type 2 diabetes, which is inconclusively ...
Chakraborty, Sandeep +9 more
core
Generation of Bioactive Hydrolysates and Peptides from Bovine Hemoglobin with In Vitro Renin, Angiotensin-I-Converting Enzyme and Dipeptidyl Peptidase-IV Inhibitory Activities [PDF]
, 2016 peer-reviewedBovine hemoglobin was selected for use in the generation of bioactive hydrolysates with potential for use as functional food ingredients for prevention of disorders such as hypertension, obesity and diabetes.
Adje +45 more
core +1 more source